In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Allogeneic stem cell transplantation (allo-SCT) has the potential to induce sustained remissions in patients with multiple myeloma (MM). Currently, allo-SCT is primarily performed in high-risk MM patients, most often in the setting of early relapse after first-line therapy with autologous SCT. Howev...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2017-09, Vol.52 (9), p.1233-1240 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1240 |
|---|---|
| container_issue | 9 |
| container_start_page | 1233 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 52 |
| creator | Oostvogels, R Uniken Venema, S M de Witte, M Raymakers, R Kuball, J Kröger, N Minnema, M C |
| description | Allogeneic stem cell transplantation (allo-SCT) has the potential to induce sustained remissions in patients with multiple myeloma (MM). Currently, allo-SCT is primarily performed in high-risk MM patients, most often in the setting of early relapse after first-line therapy with autologous SCT. However, the implementation of allo-SCT for MM is jeopardized by high treatment-related mortality (TRM) rates as well as high relapse rates. In this systematic review, we aimed to identify a safe allo-SCT strategy that has optimal 1-year results regarding mortality, relapse and severe GvHD, creating opportunities for post-transplantation strategies to maintain remissions in the high-risk group of relapsed MM patients. Eleven studies were included. Median PFS ranged from 5.2 to 36.8 months and OS was 13.0 to 63.0 months. The relapse related mortality at 1 year varied between 0 and 50% and TRM between 8 and 40%. Lowest GvHD incidences were reported for conditioning regimens with T-cell depletion using ATG or graft CD34+ selection. Similar strategies could lay the foundation for a post-transplant immune platform, this should be further evaluated in prospective clinical trials. |
| doi_str_mv | 10.1038/bmt.2017.141 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1917666115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A503411113</galeid><sourcerecordid>A503411113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-6e4d2c9a8dae7c22c7779ff4df11df013e9a331a342bb021f6456a79d10c88f53</originalsourceid><addsrcrecordid>eNp9kk2LFDEQhhtR3HH15lkCgniwx3x1utvbMPixsKDgeg6ZdGUmS9Jpk7TS_94Ms-quLCaQQOV5K1XUW1XPCV4TzLq3O5_XFJN2TTh5UK0Ib0XdMNE8rFaYiq5mTPRn1ZOUrjEmnOPmcXVGO9FTTLtVtVyMKIGK-oCCQfkAKEzZeuXQ5FQ2IXpUDvQlpFxvnAt7GMFq9HV7haz38xiKJKppQXZEEZyaEgzIzy7byQHyC7jg1TukUFpSBq9yEUf4YeHn0-qRUS7Bs5v7vPr24f3V9lN9-fnjxXZzWWvesVwL4APVveoGBa2mVLdt2xvDB0PIYDBh0CvGiGKc7naYEiN4I1TbDwTrrjMNO69en_JOMXyfIWXpbdLgnBohzEmSnrRCCEKO6Mt_0Oswx7FUJ6nglLQtwd3_KNKzpsN9mctfaq8cSDuakKPSx6_lpsGMk7KO1PoequwBvNVhBGNL_I7g1S3BAZTLhxTcnG0Y013wzQnUMaQUwcgplrnGRRIsj8aRxTjyaBxZjFPwFzdNzTsPwx_4t1MKUJ-AVJ7GPcRbXd-X8BdsDcpp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935809103</pqid></control><display><type>article</type><title>In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Oostvogels, R ; Uniken Venema, S M ; de Witte, M ; Raymakers, R ; Kuball, J ; Kröger, N ; Minnema, M C</creator><creatorcontrib>Oostvogels, R ; Uniken Venema, S M ; de Witte, M ; Raymakers, R ; Kuball, J ; Kröger, N ; Minnema, M C</creatorcontrib><description>Allogeneic stem cell transplantation (allo-SCT) has the potential to induce sustained remissions in patients with multiple myeloma (MM). Currently, allo-SCT is primarily performed in high-risk MM patients, most often in the setting of early relapse after first-line therapy with autologous SCT. However, the implementation of allo-SCT for MM is jeopardized by high treatment-related mortality (TRM) rates as well as high relapse rates. In this systematic review, we aimed to identify a safe allo-SCT strategy that has optimal 1-year results regarding mortality, relapse and severe GvHD, creating opportunities for post-transplantation strategies to maintain remissions in the high-risk group of relapsed MM patients. Eleven studies were included. Median PFS ranged from 5.2 to 36.8 months and OS was 13.0 to 63.0 months. The relapse related mortality at 1 year varied between 0 and 50% and TRM between 8 and 40%. Lowest GvHD incidences were reported for conditioning regimens with T-cell depletion using ATG or graft CD34+ selection. Similar strategies could lay the foundation for a post-transplant immune platform, this should be further evaluated in prospective clinical trials.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2017.141</identifier><identifier>PMID: 28692028</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/700/565/2319 ; 692/700/565/251 ; Autografts ; Bone marrow ; Bortezomib ; Care and treatment ; CD34 antigen ; Cell Biology ; Clinical trials ; Depletion ; Dosage and administration ; Female ; Graft-versus-host reaction ; Health aspects ; Health risk assessment ; Hematology ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Immunotherapy ; Immunotherapy - methods ; Internal Medicine ; Lymphocytes T ; Male ; Medical research ; Medicine ; Medicine & Public Health ; Mortality ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; Multiple Myeloma - therapy ; Neoplasm Recurrence, Local ; Patients ; Public Health ; review ; Risk groups ; Stem cell transplantation ; Stem Cells ; Systematic review ; Thalidomide ; Transplantation ; Transplantation Conditioning - methods ; Transplantation, Homologous - methods ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2017-09, Vol.52 (9), p.1233-1240</ispartof><rights>Macmillan Publishers Limited, part of Springer Nature. 2017</rights><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2017</rights><rights>Macmillan Publishers Limited, part of Springer Nature. 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-6e4d2c9a8dae7c22c7779ff4df11df013e9a331a342bb021f6456a79d10c88f53</citedby><cites>FETCH-LOGICAL-c483t-6e4d2c9a8dae7c22c7779ff4df11df013e9a331a342bb021f6456a79d10c88f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2017.141$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2017.141$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28692028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oostvogels, R</creatorcontrib><creatorcontrib>Uniken Venema, S M</creatorcontrib><creatorcontrib>de Witte, M</creatorcontrib><creatorcontrib>Raymakers, R</creatorcontrib><creatorcontrib>Kuball, J</creatorcontrib><creatorcontrib>Kröger, N</creatorcontrib><creatorcontrib>Minnema, M C</creatorcontrib><title>In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Allogeneic stem cell transplantation (allo-SCT) has the potential to induce sustained remissions in patients with multiple myeloma (MM). Currently, allo-SCT is primarily performed in high-risk MM patients, most often in the setting of early relapse after first-line therapy with autologous SCT. However, the implementation of allo-SCT for MM is jeopardized by high treatment-related mortality (TRM) rates as well as high relapse rates. In this systematic review, we aimed to identify a safe allo-SCT strategy that has optimal 1-year results regarding mortality, relapse and severe GvHD, creating opportunities for post-transplantation strategies to maintain remissions in the high-risk group of relapsed MM patients. Eleven studies were included. Median PFS ranged from 5.2 to 36.8 months and OS was 13.0 to 63.0 months. The relapse related mortality at 1 year varied between 0 and 50% and TRM between 8 and 40%. Lowest GvHD incidences were reported for conditioning regimens with T-cell depletion using ATG or graft CD34+ selection. Similar strategies could lay the foundation for a post-transplant immune platform, this should be further evaluated in prospective clinical trials.</description><subject>692/700/565/2319</subject><subject>692/700/565/251</subject><subject>Autografts</subject><subject>Bone marrow</subject><subject>Bortezomib</subject><subject>Care and treatment</subject><subject>CD34 antigen</subject><subject>Cell Biology</subject><subject>Clinical trials</subject><subject>Depletion</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Graft-versus-host reaction</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Internal Medicine</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>Multiple Myeloma - therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patients</subject><subject>Public Health</subject><subject>review</subject><subject>Risk groups</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Systematic review</subject><subject>Thalidomide</subject><subject>Transplantation</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous - methods</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kk2LFDEQhhtR3HH15lkCgniwx3x1utvbMPixsKDgeg6ZdGUmS9Jpk7TS_94Ms-quLCaQQOV5K1XUW1XPCV4TzLq3O5_XFJN2TTh5UK0Ib0XdMNE8rFaYiq5mTPRn1ZOUrjEmnOPmcXVGO9FTTLtVtVyMKIGK-oCCQfkAKEzZeuXQ5FQ2IXpUDvQlpFxvnAt7GMFq9HV7haz38xiKJKppQXZEEZyaEgzIzy7byQHyC7jg1TukUFpSBq9yEUf4YeHn0-qRUS7Bs5v7vPr24f3V9lN9-fnjxXZzWWvesVwL4APVveoGBa2mVLdt2xvDB0PIYDBh0CvGiGKc7naYEiN4I1TbDwTrrjMNO69en_JOMXyfIWXpbdLgnBohzEmSnrRCCEKO6Mt_0Oswx7FUJ6nglLQtwd3_KNKzpsN9mctfaq8cSDuakKPSx6_lpsGMk7KO1PoequwBvNVhBGNL_I7g1S3BAZTLhxTcnG0Y013wzQnUMaQUwcgplrnGRRIsj8aRxTjyaBxZjFPwFzdNzTsPwx_4t1MKUJ-AVJ7GPcRbXd-X8BdsDcpp</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Oostvogels, R</creator><creator>Uniken Venema, S M</creator><creator>de Witte, M</creator><creator>Raymakers, R</creator><creator>Kuball, J</creator><creator>Kröger, N</creator><creator>Minnema, M C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review</title><author>Oostvogels, R ; Uniken Venema, S M ; de Witte, M ; Raymakers, R ; Kuball, J ; Kröger, N ; Minnema, M C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-6e4d2c9a8dae7c22c7779ff4df11df013e9a331a342bb021f6456a79d10c88f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>692/700/565/2319</topic><topic>692/700/565/251</topic><topic>Autografts</topic><topic>Bone marrow</topic><topic>Bortezomib</topic><topic>Care and treatment</topic><topic>CD34 antigen</topic><topic>Cell Biology</topic><topic>Clinical trials</topic><topic>Depletion</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Graft-versus-host reaction</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Internal Medicine</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>Multiple Myeloma - therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patients</topic><topic>Public Health</topic><topic>review</topic><topic>Risk groups</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Systematic review</topic><topic>Thalidomide</topic><topic>Transplantation</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous - methods</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oostvogels, R</creatorcontrib><creatorcontrib>Uniken Venema, S M</creatorcontrib><creatorcontrib>de Witte, M</creatorcontrib><creatorcontrib>Raymakers, R</creatorcontrib><creatorcontrib>Kuball, J</creatorcontrib><creatorcontrib>Kröger, N</creatorcontrib><creatorcontrib>Minnema, M C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oostvogels, R</au><au>Uniken Venema, S M</au><au>de Witte, M</au><au>Raymakers, R</au><au>Kuball, J</au><au>Kröger, N</au><au>Minnema, M C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>52</volume><issue>9</issue><spage>1233</spage><epage>1240</epage><pages>1233-1240</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Allogeneic stem cell transplantation (allo-SCT) has the potential to induce sustained remissions in patients with multiple myeloma (MM). Currently, allo-SCT is primarily performed in high-risk MM patients, most often in the setting of early relapse after first-line therapy with autologous SCT. However, the implementation of allo-SCT for MM is jeopardized by high treatment-related mortality (TRM) rates as well as high relapse rates. In this systematic review, we aimed to identify a safe allo-SCT strategy that has optimal 1-year results regarding mortality, relapse and severe GvHD, creating opportunities for post-transplantation strategies to maintain remissions in the high-risk group of relapsed MM patients. Eleven studies were included. Median PFS ranged from 5.2 to 36.8 months and OS was 13.0 to 63.0 months. The relapse related mortality at 1 year varied between 0 and 50% and TRM between 8 and 40%. Lowest GvHD incidences were reported for conditioning regimens with T-cell depletion using ATG or graft CD34+ selection. Similar strategies could lay the foundation for a post-transplant immune platform, this should be further evaluated in prospective clinical trials.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28692028</pmid><doi>10.1038/bmt.2017.141</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2017-09, Vol.52 (9), p.1233-1240 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1917666115 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | 692/700/565/2319 692/700/565/251 Autografts Bone marrow Bortezomib Care and treatment CD34 antigen Cell Biology Clinical trials Depletion Dosage and administration Female Graft-versus-host reaction Health aspects Health risk assessment Hematology Hematopoietic Stem Cell Transplantation - methods Humans Immunotherapy Immunotherapy - methods Internal Medicine Lymphocytes T Male Medical research Medicine Medicine & Public Health Mortality Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Multiple Myeloma - therapy Neoplasm Recurrence, Local Patients Public Health review Risk groups Stem cell transplantation Stem Cells Systematic review Thalidomide Transplantation Transplantation Conditioning - methods Transplantation, Homologous - methods Transplants & implants |
| title | In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A00%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20search%20of%20the%20optimal%20platform%20for%20Post-Allogeneic%20SCT%20immunotherapy%20in%20relapsed%20multiple%20myeloma:%20a%20systematic%20review&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Oostvogels,%20R&rft.date=2017-09-01&rft.volume=52&rft.issue=9&rft.spage=1233&rft.epage=1240&rft.pages=1233-1240&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2017.141&rft_dat=%3Cgale_proqu%3EA503411113%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935809103&rft_id=info:pmid/28692028&rft_galeid=A503411113&rfr_iscdi=true |